All In Biotech

Drug Trial Radar · NCT07599176

Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors

Matched Related Donor Non-myeloablative Hematopoietic Cell Transplantation With Alemtuzumab, 400 cGy TBI, and Abatacept for Sickle Cell Disease and Beta-Thalassemia

Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Jul 8, 2026

Primary completion

Jun 30, 2032

Study completion Jun 30, 2035

Sponsor

Sponsor type
NIH
First posted
May 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 4 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a non-ablative (partial) stem cell transplant for patients with severe sickle cell disease or beta-thalassemia requiring red cell transfusions. The intensity of the transplant is slightly increased from our previous transplant regimens. The goal is to aim for higher percentage of donor cells to stably remain in the recipients long term.

Conditions

  • Sickle Cell Disease
  • Beta-thalassemia

Interventions

  • Total Body IrradiationRadiation

    Total Body Irradiation 400 cGy

  • AlemtuzumabDrug

    1 mg/kg

  • AbataceptDrug

    10 mg/kg x 6

  • Research blood drawOther

    About 5 tablespoons of blood will be collected from donors for research purposes.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Donor myeloid chimerismTime frame: 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Institutes of Health Clinical Center

    Bethesda, Maryland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.